Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Trial details
- Registry ID
- NCT02598661
- Phase
- Phase 2, Phase 3
The FDA approved Imetelstat Sodium (GRN163L) on 6 Jun 2024.
Drug identity checked against registry records
Also recorded as GRN163L
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)NCT02598661 | Geron Corporation | Phase 2, Phase 3 | Active not recruiting | 2023-10-13Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2024-06-06Day | Imetelstat Sodium | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA217779", "applicant_as_listed_by_fda": "GERON", "brand_names": ["RYTELO"], "active_ingredients": ["IMETELSTAT SODIUM"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20240606", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |